Imarech (Imatinib mesylate) Blood Cancer medicine
Name of Medicine: Imarech
Composition: Imatinib Mesylate 400mg
Chemical Formula: C30H35N7O4S
Description: Imarech is a formulation of Imatinib Mesylate, available as tablets in the strength of 400mg for oral use.
What is Imarech?
Imarech is a prescription drug that belongs to a class of medications known as anti-cancer agents. It is an effective formulation of a kinase inhibitor namely Imatinib Mesylate. Imarech (Imatinib Mesylate) tablet inhibits the proliferation and induces apoptosis (planned cell death) in BCR-ABL positive cells (cancer cells).
Clinical Relevance
Imarech, comprising Imatinib Mesylate, is a kinase inhibitor prescribed for the treatment of:
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP); provided- after the failure of interferon-alpha therapy.
Ph+ CML in chronic phase (newly diagnosed or recurred).
Relapsed Philadelphia chromosome-positive agents acute lymphoblastic leukemia (Ph+ ALL).
Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements.
Aggressive systemic mastocytosis (ASM).
Hypereosinophilic syndrome (HES).
Chronic eosinophilic leukemia (CEL).
Metastatic dermatofibrosarcoma protuberans (DFSP)
Positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
-
Category
No comments found